Editorial:primary Prevention of Coronary Heart Disease with Lipid Lowering Therapy

Author： Bernini F.   Paoletti R.  

Publisher： Academic Press

ISSN： 1043-6618

Source： Pharmacological Research, Vol.35, Iss.3, 1997-03, pp. : 167-167

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

By Nieminen Tuomo   Käähöönen Mika   Viiri Leena E   Gröönroos Paula   Lehtimääki Terho  

Pharmacogenomics, Vol. 9, Iss. 10, 2008-10 ,pp. : 1475-1486

Future Medicine

Access to resources Recommend Favorite

Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly: Opportunities and Challenges

By Robinson Jennifer G.  

Drugs & Aging, Vol. 26, Iss. 11, 2009-11 ,pp. : 917-931

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US

By Rosen Virginia M.  

PharmacoEconomics, Vol. 28, Iss. 1, 2010-01 ,pp. : 47-60

Adis International

Access to resources Recommend Favorite

Primary prevention strategies for lipid-lowering: cost effectiveness

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 575, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women

By  

Current Pharmaceutical Design, Vol. 15, Iss. 10, 2009-04 ,pp. : 1054-1062

Bentham Science Publishers

Access to resources Recommend Favorite